Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMARA: Proteomics and Metabolic Labelling for Alzheimer's Diagnosis
NCT02263235Terminated
- Sponsor
- CHU Montpellier
- Start
- Oct 2013
- Primary completion
- May 2018
- Countries
- 1
01
Overview
Open-label trial, sponsored by CHU Montpellier. Primary endpoint: C13 Leucine incorporation in Amyloid peptides (1-40, 1-42) at 1.5 years. Started Oct 2013; status: terminated.
Beyond the preview
Go deeper on NCT02263235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263235.